ZIF-C as non-viral delivery system for CRISPR/Cas9 mediated hTERT knockdown in cancer cells

12 August 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Telomerase, a ribonucleoprotein coded by the hTERT gene, plays an important role in cellular immortalization and carcinogenesis. hTERT is a suitable target for cancer therapeutics as its activity is highly upregulated in 85-90% of cancer cells but absent in normal somatic cells. Here, we target the hTERT gene at the DNA level by applying the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 technology encapsulated in a recently discovered Metal-Organic Framework (MOF). We show that the MOF subtype ‘ZIF-C’ can efficiently load the hTERT targeting CRISPR system (CrhTERT@ZIF-C) and protect it from enzymatic degradation. The CrhTERT@ZIF-C is endocytosed by cancer cells and successfully disrupts the hTERT gene. The resultant inhibition of hTERT decreases cellular proliferation and causes apoptotic cancer cell death. Furthermore, hTERT knockdown shows a significant reduction in tumor metastasis and alters protein expression. Thus, our results conclusively establish ZIF-C based targeting of hTERT as a highly promising and novel approach for gene therapy in cancer.


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.